GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (NAS:CLRB) » Definitions » Shiller PE Ratio

Cellectar Biosciences (Cellectar Biosciences) Shiller PE Ratio : (As of Apr. 30, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Cellectar Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectar Biosciences Shiller PE Ratio Historical Data

The historical data trend for Cellectar Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Shiller PE Ratio Chart

Cellectar Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cellectar Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cellectar Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Cellectar Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectar Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Shiller PE Ratio falls into.



Cellectar Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cellectar Biosciences's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Cellectar Biosciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.4/129.4194*129.4194
=-0.400

Current CPI (Dec. 2023) = 129.4194.

Cellectar Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1,030.000 99.695 -1,337.105
201406 -730.000 100.560 -939.505
201409 60.000 100.428 77.321
201412 -442.591 99.070 -578.177
201503 -304.000 99.621 -394.931
201506 -302.000 100.684 -388.192
201509 -246.000 100.392 -317.130
201512 150.000 99.792 194.533
201603 91.000 100.470 117.220
201606 -49.000 101.688 -62.363
201609 -43.000 101.861 -54.634
201612 -55.604 101.863 -70.646
201703 -24.000 102.862 -30.196
201706 -23.200 103.349 -29.052
201709 -25.800 104.136 -32.064
201712 -34.000 104.011 -42.306
201803 -20.700 105.290 -25.444
201806 -16.900 106.317 -20.572
201809 -16.500 106.507 -20.050
201812 -8.088 105.998 -9.875
201903 -7.600 107.251 -9.171
201906 -4.600 108.070 -5.509
201909 -4.200 108.329 -5.018
201912 -3.300 108.420 -3.939
202003 -4.200 108.902 -4.991
202006 -2.600 108.767 -3.094
202009 -1.500 109.815 -1.768
202012 -0.700 109.897 -0.824
202103 -1.300 111.754 -1.505
202106 -1.140 114.631 -1.287
202109 -0.970 115.734 -1.085
202112 -0.960 117.630 -1.056
202203 -1.000 121.301 -1.067
202206 -1.220 125.017 -1.263
202209 -1.280 125.227 -1.323
202212 -0.550 125.222 -0.568
202303 -0.760 127.348 -0.772
202306 -0.730 128.729 -0.734
202309 -1.210 129.860 -1.206
202312 -0.400 129.419 -0.400

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cellectar Biosciences  (NAS:CLRB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cellectar Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences (Cellectar Biosciences) Business Description

Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Executives
Andrei Shustov officer: Senior Vice President, Medical 7 PARKLAND DRIVE, MILFORD NJ 08848
Darrell Shane Lea officer: Chief Commercial Officer 7 PARKLAND DRIVE, MILFORD NJ 08848
Chad J Kolean officer: Chief Financial Officer C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716
Douglas J Swirsky director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Frederick W Driscoll director
Asher Chanan-khan director C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932
James V Caruso director, officer: President and CEO C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Jarrod Longcor officer: Chief Business Officer C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Friend John E. Ii officer: VP, Chief Medical Officer 26 ORCHARD LANE, COLT NECK NJ 07722
John Neis director 505 S. ROSA ROAD, SUITE 201, MADISON WI 53719
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Igor D Grachev officer: Chief Medical Officer 15 REID LANE, MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD, MALVERN PA 19355

Cellectar Biosciences (Cellectar Biosciences) Headlines